Dry eye pearls for young ophthalmologists

Ophthalmology Times EuropeOphthalmology Times Europe April 2022
Volume 18
Issue 03

It is particularly important to identify any signs of meibomian gland disease in patients to prevent gland atrophy and loss of function.

Dry eye pearls for young ophthalmologists

“Think of dry eye in everything you do.” This advice was given to new ophthalmologists by Dr Sheri Rowen, the medical director of NVision Eye Centers in Newport Beach, California, United States.

Dry eye sounds simple but is actually a far-reaching, multifactorial disease of the ocular surface that causes loss of homeostasis of the tear film. According to the Tear Film and Ocular Surface Society Dry Eye Workshop II definition, this loss of homeostasis is accompanied by ocular symptoms in which tear film instability, hyperosmolarity, ocular surface inflammation and damage and neurosensory abnormalities all play aetiological roles.

Meibomian gland dysfunction

Take home points: MGD often goes undiagnosed; ophthalmologists must look for MGD and learn how to express the glands to make the diagnosis; and they should check the quality and quantity of the meibum.

Dr Rowen stated that meibomian gland disease (MGD) is one of the major problems in dry eye disease. Normal glands are symmetrical and are even the same length. They are not dilated. In contrast, with progression of dry eye disease, the glands become truncated and dilated in moderate cases, with subsequent glandular atrophy (dropout) and extreme loss of function in severe cases.

Dr Rowen emphasised the importance of recognising MGD progression to ensure appropriate treatment. Youth and gender are not protective against MGD. Dr Rowen discussed severe cases of gland atrophy in patients in their 20s who presented with complaints of dry eye.

In a 22-year-old man, severe atrophy was already present; in a 26-year-old man who wanted to undergo LASIK surgery for contact lens intolerance, the meibomian glands were almost completely deteriorated.

Gland dropout can start early, often in patients as young as 8–16 years. “Ophthalmologists must be able to recognise this is happening to young patients of both genders to be able to provide appropriate treatment,” Dr Rowen said.

“If these patients are identified when they are young, or optometrists are educated to recognise these cases early [on], ophthalmologists will be able to help them early [on] to avoid the development of atrophy,” Dr Rowen concluded. “Ophthalmologists should always stain the ocular surface with fluorescein and lissamine stains, express the glands and use a questionnaire. This will ensure the identification of 97% of patients with dry eye.”

Sheri Rowen, MD
E: srowen10@gmail.com
This article is adapted from Dr Rowen’s presentation at the virtual Real World Ophthalmology Autumn 2021 meeting. Dr Rowen is a consultant to Alcon and Johnson & Johnson.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.